WEST CHESTER, PA — Centinel Spine®, LLC recently announced record first quarter 2023 worldwide financial results in its Motion Preservation business. Record growth was primarily driven by continued strong adoption of the Company’s new prodisc C Vivo and prodisc C SK cervical TDR system.
One of the recent new users of the new prodisc cervical system, neurosurgeon Tejpaul Pannu, MD of Michigan Head & Spine Institute, commented, “With the launch of the new prodisc C Vivo and prodisc C SK cervical TDR system, I now have the ability to match the particular disc I use to a variety of patient factors. The prodisc cervical system allows me to select a domed or flat implant coupled with either keel or spiked fixation. This optionality can be a benefit and is not available from any other total disc manufacturer.”
Centinel Spine CEO Steve Murray shared, “We have seen a tremendous start to 2023, driven by the rapid uptake of prodisc C Vivo and prodisc C SK, which is the first TDR system to offer anatomic designs that match the disc to the needs of the surgeon and patient. We expect this momentum to continue throughout the year as we continue to expand availability of the new system and provide more access to surgeons and their patients.”
First Quarter 2023 Highlights
First quarter 2023 revenue for the Company’s worldwide Motion Preservation business exceeded $14 million (a record for the company), with growth of 38% over Q1 2022 and sequential growth of 10% over Q4 2022 (previous record quarter). Overall growth in the quarter was primarily driven by the September 2022 limited release of the new prodisc C Vivo and prodisc C SK cervical TDR system in the U.S. and continued global expansion in the prodisc L lumbar business. The U.S. Motion Preservation business grew 39% for the first quarter versus first quarter 2022, while the International Motion Preservation business grew 35%.
Since the Company initiated the limited U.S. launch of prodisc C Vivo and prodisc SK, rapid market acceptance of the new cervical TDR system has continued. Through the end of the first quarter 2023, almost 900 cases were completed with the new system, generating more than $6 million in sales with almost 200 new surgeon users. The adoption of the new cervical TDR system accelerated in the first quarter, as exhibited by 60% growth in average daily cases and almost 45% growth in additional new users versus the prior quarter. Over two-thirds of the surgeons using the new prodisc cervical system were repeat users, and an estimated 70% of users were competitive conversions. New surgeon users were added with the support of a global medical educational initiative that trained almost 160 surgeons in the quarter.
Strong commercial traction for the overall U.S. cervical and lumbar prodisc TDR business continued, demonstrated by total user growth of more than 20% over the first quarter 2022 and sequential growth exceeding 10% versus fourth quarter 2022. The number of U.S. facilities utilizing the Company’s Motion Preservation products increased almost 30%, and the number of distributors selling the products expanded by upwards of 15% versus first quarter 2022.
Centinel Spine’s prodisc portfolio represents the most comprehensive TDR systems in the world, offering both cervical and lumbar implants with anatomically-differentiated designs. Centinel Spine is the only company with FDA approval for both cervical and lumbar TDR systems. All of the prodisc cervical and lumbar devices incorporate prodisc CORE technology, the basis behind the predictable clinical outcomes of the prodisc platform after 30 years and over 240,000 implantations worldwide.*
- Data on file with Company.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.